ERBB2 and breast cancer: Stratification of patients into groups according to molecular subtypes showed that compared with the normal breast samples MIAT expression was not changed in the triple positive (ER, PR, and HER2 positive) samples, but was significantly increased in ER, PR +ve, HER –ve breast cancer subtypes and in triple negative breast cancer (TNBC) (Figure 1D).